Credit Suisse Downgrades Myriad Genetics (MYGN) to Underperform

Credit Suisse downgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Underperform with a price target of $30.00 (from $35.00) citing execution uncertainty following in-line Q2 but significantly lowered FY 2015 guidance.

Analyst V. Divan said the lower guidance appears mainly due to timing-related issues, but continued uncertainties and lack of
visibility on the company's business make it difficult to recommend MYGN as an attractive investment at this time.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $38.12 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• Intuitive Surgical (ISRG) PT Raised to $435 at Piper Sandler